ArticleHuman vaccines & immunotherapeutics2019
Experience implementing a university-based mass immunization program in response to a meningococcal B outbreak.
Article in Human vaccines & immunotherapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Public health management of invasive meningococcal disease outbreaks: worldwide 1973-2018, a systematic review.BMC public health · 2024Pooled it
- Article
- Policies for the immunization against serogroup B meningococcus for adolescents immunized during the first two years of life: A mini review.Human vaccines & immunotherapeutics · 2024Review
- Evaluation methods for vaccination campaigns on college campuses: A scoping review.Vaccine: X · 2022Article
- Rationale for the Development of a Pentavalent Meningococcal Vaccine: A US-Focused Review.Infectious diseases and therapy · 2022Review
- Agent-based modelling of reactive vaccination of workplaces and schools against COVID-19.Nature communications · 2022Article
- Meningococcal Disease Outbreaks: A Moving Target and a Case for Routine Preventative Vaccination.Infectious diseases and therapy · 2021Review
- Increasing awareness and uptake of the MenB vaccine on a large university campus.Human vaccines & immunotherapeutics · 2021Article
- Best Practices for COVID-19 Mass Vaccination Clinics.Annals of family medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neisseria meningitidis serogroup B (MenB) has caused several recent outbreaks of meningococcal disease on US college campuses. In January 2015, a case of MenB was reported at a university in Oregon, culminating in an outbreak with a total of 7 cases (including 1 fatality) identified over a 5-month period. In response to the outbreak, the university organized a mass immunization campaign with 4 "opt-in" immunization clinics. The preparation, challenges, and resources required for organization and implementation of a mass immunization program in response to an outbreak at a large public university are discussed herein. Based on the logistical challenges as well as resource expenditures associated with planning and executing a mass immunization effort, this experience illustrates that proactive, routine immunization of incoming students is the best strategy for MenB outbreak prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.